Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems; Hideki Hasegawa; Roberto Accolla; Charles Bangham; Ali Bazarbachi; Umberto Bertazzoni; Anna Barbara de Freitas Carneiro-Proietti; Hua Cheng; Luigi Chieco-Bianchi; Vincenzo Ciminale; Jordana Coelho-dos-Reis; José Esparza; Robert C. Gallo; Antoine Gessain; Eduardo Gotuzzo; William Hall; Joseph Harford; Olivier Hermine; Steven Jacobson; Beatrice Macchi; Calum Macpherson; Renaud Mahieux; Masao Matsuoka; Edward Murphy; Jean Marie Peloponese; Viviana Simon; Yutaka Tagaya; Graham P. Taylor; Toshiki Watanabe; Yoshihisa Yamano

doi:10.1016/j.antiviral.2016.10.015

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Luc Willems
, Hideki Hasegawa
, Roberto Accolla
, Charles Bangham
, Ali Bazarbachi
, Umberto Bertazzoni
, Anna Barbara de Freitas Carneiro-Proietti
, Hua Cheng
, Luigi Chieco-Bianchi
, Vincenzo Ciminale
, Jordana Coelho-dos-Reis
, José Esparza
, Robert C. Gallo
, Antoine Gessain
, Eduardo Gotuzzo
, William Hall
, Joseph Harford
, Olivier Hermine
, Steven Jacobson
, Beatrice Macchi

Calum Macpherson, Renaud Mahieux, Masao Matsuoka, Edward Murphy, Jean Marie Peloponese, Viviana Simon, Yutaka Tagaya, Graham P. Taylor, Toshiki Watanabe, Yoshihisa Yamano

Université de Liège
Chairs of the HTLV Taskforce of the Global Virus Network
National Institute of Infectious Diseases
Insubria University
Imperial College London
American University of Beirut
University of Verona
Fundação Hemominas
Institute of Human Virology
University of Padova
Oswaldo Cruz Foundation
Institut Pasteur, Paris
Centre for Research in Infectious Disease
National Cancer Institute (NCI)
Hôpital Necker - Enfants Malades
National Institute of Neurological Disorders and Stroke
Tor Vergata University of Rome
St. George's University Grenada
Ecole Normale Supérieure de Lyon
Kyoto University
University of California San Francisco Center for Tuberculosis
Université de Montpellier
Icahn School of Medicine at Mount Sinai
University of Tokyo
St. Marianna University School of Medicine

Research output: Contribution to journal › Review article › peer-review

125 Scopus citations

Abstract

Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

Original language	English
Pages (from-to)	41-48
Number of pages	8
Journal	Antiviral Research
Volume	137
DOIs	https://doi.org/10.1016/j.antiviral.2016.10.015
State	Published - 1 Jan 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 5 Gender Equality

Keywords

HTLV-1
Leukemia
Oncogene
Retrovirus
Vaccine

Access to Document

10.1016/j.antiviral.2016.10.015

Cite this

Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., Carneiro-Proietti, A. B. D. F., Cheng, H., Chieco-Bianchi, L., Ciminale, V., Coelho-dos-Reis, J., Esparza, J., Gallo, R. C., Gessain, A., Gotuzzo, E., Hall, W., Harford, J., Hermine, O., Jacobson, S., ... Yamano, Y. (2017). Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 137, 41-48. https://doi.org/10.1016/j.antiviral.2016.10.015

@article{4c2e4e85fd5f4c148954ba32c0ffcd09,

title = "Reducing the global burden of HTLV-1 infection: An agenda for research and action",

abstract = "Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.",

keywords = "HTLV-1, Leukemia, Oncogene, Retrovirus, Vaccine",

author = "Luc Willems and Hideki Hasegawa and Roberto Accolla and Charles Bangham and Ali Bazarbachi and Umberto Bertazzoni and Carneiro-Proietti, \{Anna Barbara de Freitas\} and Hua Cheng and Luigi Chieco-Bianchi and Vincenzo Ciminale and Jordana Coelho-dos-Reis and Jos{\'e} Esparza and Gallo, \{Robert C.\} and Antoine Gessain and Eduardo Gotuzzo and William Hall and Joseph Harford and Olivier Hermine and Steven Jacobson and Beatrice Macchi and Calum Macpherson and Renaud Mahieux and Masao Matsuoka and Edward Murphy and Peloponese, \{Jean Marie\} and Viviana Simon and Yutaka Tagaya and Taylor, \{Graham P.\} and Toshiki Watanabe and Yoshihisa Yamano",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.antiviral.2016.10.015",

language = "Ingl{\'e}s",

volume = "137",

pages = "41--48",

journal = "Antiviral Research",

issn = "0166-3542",

}

Willems, L, Hasegawa, H, Accolla, R, Bangham, C, Bazarbachi, A, Bertazzoni, U, Carneiro-Proietti, ABDF, Cheng, H, Chieco-Bianchi, L, Ciminale, V, Coelho-dos-Reis, J, Esparza, J, Gallo, RC, Gessain, A, Gotuzzo, E, Hall, W, Harford, J, Hermine, O, Jacobson, S, Macchi, B, Macpherson, C, Mahieux, R, Matsuoka, M, Murphy, E, Peloponese, JM, Simon, V, Tagaya, Y, Taylor, GP, Watanabe, T & Yamano, Y 2017, 'Reducing the global burden of HTLV-1 infection: An agenda for research and action', Antiviral Research, vol. 137, pp. 41-48. https://doi.org/10.1016/j.antiviral.2016.10.015

TY - JOUR

T1 - Reducing the global burden of HTLV-1 infection

T2 - An agenda for research and action

AU - Willems, Luc

AU - Hasegawa, Hideki

AU - Accolla, Roberto

AU - Bangham, Charles

AU - Bazarbachi, Ali

AU - Bertazzoni, Umberto

AU - Carneiro-Proietti, Anna Barbara de Freitas

AU - Cheng, Hua

AU - Chieco-Bianchi, Luigi

AU - Ciminale, Vincenzo

AU - Coelho-dos-Reis, Jordana

AU - Esparza, José

AU - Gallo, Robert C.

AU - Gessain, Antoine

AU - Gotuzzo, Eduardo

AU - Hall, William

AU - Harford, Joseph

AU - Hermine, Olivier

AU - Jacobson, Steven

AU - Macchi, Beatrice

AU - Macpherson, Calum

AU - Mahieux, Renaud

AU - Matsuoka, Masao

AU - Murphy, Edward

AU - Peloponese, Jean Marie

AU - Simon, Viviana

AU - Tagaya, Yutaka

AU - Taylor, Graham P.

AU - Watanabe, Toshiki

AU - Yamano, Yoshihisa

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

AB - Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

KW - HTLV-1

KW - Leukemia

KW - Oncogene

KW - Retrovirus

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85002245143

U2 - 10.1016/j.antiviral.2016.10.015

DO - 10.1016/j.antiviral.2016.10.015

M3 - Artículo de revisión

C2 - 27840202

AN - SCOPUS:85002245143

SN - 0166-3542

VL - 137

SP - 41

EP - 48

JO - Antiviral Research

JF - Antiviral Research

ER -

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this